![Vials with the AstraZeneca COVID-19 vaccine against the novel coronavirus are pictured at the vaccination center in Nuremberg, southern Germany, on March 18, 2021. - Germany on March 15 halted the use of AstraZeneca's coronavirus vaccine after reported blood clotting incidents in Europe, saying that a closer look was necessary. (Photo by Christof STACHE / AFP) / The erroneous mention[s] appearing in the metadata of this photo by Christof STACHE has been modified in AFP systems in the following manner: [AstraZeneca] instead of [AstraZenaca]. Please immediately remove the erroneous mention[s] from all your online services and delete it (them) from your servers. If you have been authorized by AFP to distribute it (them) to third parties, please ensure that the same actions are carried out by them. Failure to promptly comply with these instructions will entail liability on your part for any continued or post notification usage. Therefore we thank you very much for all your attention and prompt action. We are sorry for the inconvenience this notification may cause and remain at your disposal for any further information you may require. 1231789942](https://i.cbc.ca/1.5960124.1616497899!/fileImage/httpImage/image.jpg_gen/derivatives/16x9_460/1231789942.jpg)
AstraZeneca said its COVID-19 vaccine had a 76 per cent efficacy rate at preventing symptomatic illness in a new analysis of its major U.S. trial — slightly lower than the level announced earlier this week in a report that was criticized for using outdated information.
from CBC | Health News https://ift.tt/3lOp908
Aucun commentaire:
Enregistrer un commentaire